NTRB — what changed in the latest 10-Q
A section-by-section comparison of NTRB's newest periodic SEC filing (10-K/10-Q) against the prior same-form filing: paragraphs added and removed per section, with verbatim excerpts. Purely a deterministic text diff — no similarity scores, no directional read, not investment advice.
Comparing 10-Q · 2026-06-11 vs the prior 10-Q · 2025-12-11
| Section | Outcome | Added | Removed | Minor | Unchanged |
|---|---|---|---|---|---|
| MD&A | Text added/removed | +2 | −9 | ~10 | 11 |
| Controls & procedures | No paragraph-level changes | 0 | 0 | 0 | 4 |
| Legal proceedings | Text added/removed | +29 | −75 | ~22 | 34 |
| Risk factors | Text added/removed | +2 | −1 | ~1 | 18 |
Counts are paragraphs; added/removed means text added or removed vs the prior filing — no direction or judgement implied.
Not shown (absent or not faithfully extractable): Market risk (Item 3), Other information
Representative excerpts
Up to 5 excerpts of about 300 characters per section, quoted verbatim from the two SEC filings.
MD&A
Text added vs the prior filing · source: 10-Q · 2026-06-11
For the three months ending April 30, 2026, we used cash of $563,104 in our operations. The principal adjustments to our net loss of $1,241,956 were depreciation and amortization of $34,177, and the issuance of warrants for services in the amount of $552,458.
For the three months ending April 30, 2026, no cash was provided from financing activities .
Text removed vs the prior filing · source: 10-Q · 2025-12-11
For the nine months ending October 31, 2025, we generated revenue of $1,635,942 and our revenue costs were $1,158,575, resulting in a gross profit of $477,367. For the nine months ending October 31, 2024, we generated revenue of $1,497,158 and our costs of revenue were $1,039,785, resulting in a gro…
For the nine months ending October 31, 2025, our selling, general and administrative expenses were $6,071,320, primarily legal, accounting and compensation expenses compared to $2,554,155 for the nine months ending October 31, 2024. The increase from 2024 is primarily attributable to increases in eq…
During the nine months ending October 31, 2025, the Company incurred research and development expenses of its Aversa Fentanyl product of $1,703,093, primarily of salaries and increases in development costs from Kindeva as compared to $2,629,278 for the nine months ending October 31, 2024. The decrea…
We incurred interest expenses of $17,201 for the nine months ending October 31, 2025, as compared to $17,668 for the nine months ending October 31, 2024.
Interest income for the nine months ending October 31, 2025 was $52,674 as compared to $145,585 for the nine months ending October 31, 2024. The decrease is primarily due to cash used in the Company development operations.
Legal proceedings
Text added vs the prior filing · source: 10-Q · 2026-06-11
Operating lease liability-net of current portion 40,350 48,305
Net loss per share attributable to common stockholders - basic and diluted $(0.10) $(0.12)
Weighted average common shares outstanding - basic and diluted 12,155,983 11,125,800
Proceeds from sale of common stock and exercise of warrants - -
as of and for the Three Months Ended April 30, 2026 and 2025
Text removed vs the prior filing · source: 10-Q · 2025-12-11
Employee stock options exercised for settlement of debt 317,110 120,000 120 -
Number of Number of Paid In Comprehensive Accumulated Treasury
Total shares Amount shares Amount Capital Income(Loss) Deficit Stock
Common stock and warrants issued for conversion of debt 672,958 76,230 76 -
Number of Number of Paid In Comprehensive Accumulated Treasury
Risk factors
Text added vs the prior filing · source: 10-Q · 2026-06-11
The United States at the time of this filing is involved with a war with Iran, the outcome of which could result in changes adverse to us in domestic and international markets, including on tariffs and health care and medical products. These changes could affect our promotional activities and our pr…
There is further economic uncertainty concerning economic policies being pursued by the current administration in the United States that may affect the costs and timing of the process of bringing our products to market through approvals with the FDA.
Text removed vs the prior filing · source: 10-Q · 2025-12-11
There is economic uncertainty concerning economic policies being pursued by the current administration in the United States that may affect the costs and timing of the process of bringing our products to market through approvals with the FDA.
How to read Risk Factors (Item 1A) in a 10-Q
A 10-Q risk-factor section usually takes one of three forms; this page classifies it as one of:
- Pointer — the filer states there have been no material changes and points back to the annual 10-K risk factors; there is no own risk text to compare this quarter.
- Partial update — the filer carves out specific updated risks ("except as set forth below"); the excerpts show exactly what is new this quarter.
- Restated in full — the quarter carries the complete risk-factor text. When the prior quarter was only a pointer there is no prior full text to diff against, so the page flags the section as restated instead.
This describes the filing structure only — it is never a judgement on whether risk went up or down.
Source: text-level diff of the two SEC EDGAR filings · deterministic (no AI-generated content) · for reference only · not investment advice